Marex Group Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Der Umsatz von Marex Group wird voraussichtlich um 7.3% pro Jahr zurückgehen, während der Jahresgewinn um 14.9% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 8.2% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.2% betragen.
Wichtige Informationen
14.9%
Wachstumsrate der Gewinne
8.21%
EPS-Wachstumsrate
| Capital Markets Gewinnwachstum | 11.5% |
| Wachstumsrate der Einnahmen | -7.3% |
| Zukünftige Eigenkapitalrendite | 21.22% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 06 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyse-Update • May 07
MRX: Higher Margins And Q1 2026 Outlook Will Support Measured Upside
Analysts have lifted Marex Group's price target from $50.29 to $55.00 as they now factor in a higher profit margin of about 20.9% and a lower future P/E of roughly 9.7, despite softer revenue growth assumptions and a slightly higher discount rate. What's in the News Marex Group issued earnings guidance for the first quarter ended March 31, 2026, with expected revenues in a range of $667 million to $697 million, compared with Q1 2025 revenues of $467 million (Key Developments).
Analyse-Update • Apr 22
MRX: Higher Fair Value And Lower Future P/E Will Support Upside
Analysts have lifted their fair value estimate for Marex Group from $61.00 to $66.00, citing updated assumptions for modest positive revenue growth, a slightly higher profit margin, and a lower future P/E of 11.40 compared with the prior 13.35. What's in the News Marex Group issued earnings guidance for the quarter ending March 31, 2026, with expected revenues in a range of $667 million to $697 million, compared with Q1 2025 revenues of $467 million (Key Developments).
Analyse-Update • Apr 07
MRX: Rich Earnings Multiple Will Face Test From Softer Revenue Outlook
Analysts have inched their price targets for Marex Group higher by a few dollars into the mid $40s, reflecting updated views on revenue trends, margins, and a lower forward P/E assumption in recent TD Cowen, Piper Sandler, and Barclays research. Analyst Commentary Recent research reflects a mixed tone, with some optimism on Marex Group's revenue and margin outlook, alongside more cautious views on where the shares should trade relative to sector peers.Analyse-Update • Mar 24
MRX: Volatility And Trading Volumes Will Test Fairly Priced Shares
Analysts have lifted their average price target on Marex Group by mid single digits. Recent moves include $7 and $5 increases, citing updated assumptions for revenue trends, profit margins, and a lower implied future P/E multiple despite a slightly higher discount rate.Analyse-Update • Mar 09
MRX: Higher Trading Volumes And Supportive P/E Will Drive Future Upside
Analysts have lifted their average price target on Marex Group to $61, citing updated views on revenue trajectory, profit margins, and a modestly higher future P/E multiple informed by recent Street research revisions from TD Cowen, Piper Sandler, and Barclays. Analyst Commentary Bullish analysts are leaning into Marex Group's execution by lifting their individual price targets, which helps explain the higher Street average.Analyse-Update • Feb 23
MRX: Rising Trading Volumes And Volatility Will Support Earnings Power
Narrative update on Marex Group Analysts have nudged their Marex Group price targets higher by $7 and $5 in recent updates, while one cut a target by $1 to $49. These changes reflect adjusted views on volumes, volatility, and earnings potential rather than a change to our $61 fair value estimate.Analyse-Update • Feb 07
MRX: Higher Volatility And Volumes Will Support Earnings Power Going Forward
The analyst price target for Marex Group has increased from $56 to $61, with analysts citing updated views on revenue trends, profit margins, and future P/E assumptions reflected in recent research from TD Cowen, Piper Sandler, and Barclays. Analyst Commentary Recent research updates show bullish analysts lifting their fair value estimates for Marex Group, with the latest round of work incorporating refreshed views on revenue trends, margin resilience, and P/E assumptions.Analyse-Update • Jan 23
MRX: US Expansion And Higher Trading Volumes Will Support Future Upside
Analysts have raised their price targets on Marex Group, reflecting a revised fair value estimate from $47.71 to $50.29 as they factor in updated expectations around volumes, revenue trends, margins, and future P/E assumptions following recent sector research. Analyst Commentary Recent research updates on Marex Group show a mix of optimism and caution as analysts refresh their models ahead of upcoming results and sector comparisons.Analyse-Update • Jan 08
MRX: Rising Trading Activity Will Support Earnings Power Despite Slight Price Trim
Analysts have trimmed their price target on Marex Group to US$49 from US$50, citing refreshed views on sector volumes and volatility while keeping fair value and key valuation inputs broadly unchanged. Analyst Commentary Bullish analysts are treating the lower US$49 price target as a fine tuning rather than a reset, keeping their broader view on Marex Group intact while they refresh assumptions for sector activity.Analyse-Update • Dec 23
MRX Will Benefit From Expanding US Structured Products And Margin Resilience
Analysts have trimmed their price target on Marex Group by 4 percent to $56.00, citing slightly higher discount rates and weaker revenue growth expectations, partly offset by improved profit margin forecasts and a more attractive forward earnings multiple. What's in the News Marex Group launched a US structured products business targeting RIAs, broker dealers, and private banks.Analyse-Update • Dec 09
MRX: US Expansion Will Drive Future Upside Despite Pending Securities Lawsuits
Narrative Update on Marex Group Price Target Analysts have modestly reduced their averaged price target on Marex Group from approximately $49.00 to about $47.70. This reflects slightly weaker top line growth assumptions, partially offset by expectations for improved profit margins and a marginally lower future price to earnings multiple.Seeking Alpha • Dec 01
Unfortunate Post-IPO Realities Have Set In For Marex Group
Summary Marex Group (MRX) is rated Hold due to slowing earnings growth and recent reliance on non-organic growth. MRX has pursued aggressive acquisitions, improving diversification but raising risks of shareholder dilution and integration challenges. The company maintains strong revenue growth and a conservative dividend payout, but its yield remains below industry averages. Despite its current attractive valuation, future prospects for profit growth and mixed insider activity limit the stock's near-term upside potential. Read the full article on Seeking AlphaAnalyse-Update • Nov 25
MRX: Diversified US Expansion Will Drive Recovery Despite Securities Lawsuit Risk
Analysts have raised their price target for Marex Group from $47.67 to $49.00, citing updated assumptions around profit margins and discount rates, which support a modestly higher valuation. What's in the News Marex Group has launched its structured products business in the United States, led by Scott Kerbel.Analyse-Update • Nov 06
MRX: Revenue Outlook Will Support Rebound Despite Ongoing Class Action Lawsuits
Analysts have made a minor upward adjustment to the price target for Marex Group, now set at $47.67. This change is based on slight improvements in the revenue growth outlook and a stable discount rate.Analyse-Update • Oct 23
Analysts Lower Marex Group Price Target Amid Accounting Allegations and Revised Profit Outlook
Analysts have slightly lowered their price target for Marex Group from $49.33 to $47.67. This change reflects recent updates to the company’s growth and profitability outlook.Analyse-Update • Oct 08
Digitalization And M&A Will Unlock Global Market Potential
Analysts have lowered their price target for Marex Group from $50.89 to $49.33, citing slightly reduced profit margin forecasts and modestly improved revenue growth projections. What's in the News NINGI Research disclosed a short position in Marex Group, alleging the company used opaque off-balance-sheet entities, fictitious transactions, and misleading disclosures to obscure losses and inflate profits (Periodical).Analyseartikel • Aug 06
Here's Why Marex Group (NASDAQ:MRX) Has Caught The Eye Of Investors
NasdaqGS:MRX 1 Year Share Price vs Fair Value Explore Marex Group's Fair Values from the Community and select yours...
Neue Analyse • Apr 27
Acquisitions Will Fuel APAC And Middle East Expansion
Strong market share gains and acquisition integration are driving revenue growth and expanding product offerings and geographic reach.Analyseartikel • Apr 10
Further Upside For Marex Group plc (NASDAQ:MRX) Shares Could Introduce Price Risks After 26% Bounce
Marex Group plc ( NASDAQ:MRX ) shareholders have had their patience rewarded with a 26% share price jump in the last...Analyseartikel • Dec 25
Many Still Looking Away From Marex Group plc (NASDAQ:MRX)
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 2,855 | 511 | N/A | N/A | 3 |
| 12/31/2027 | 2,588 | 439 | N/A | N/A | 7 |
| 12/31/2026 | 2,567 | 397 | N/A | N/A | 3 |
| 3/31/2026 | 3,266 | 334 | N/A | N/A | N/A |
| 12/31/2025 | 2,870 | 294 | 648 | 668 | N/A |
| 9/30/2025 | 2,668 | 266 | N/A | N/A | N/A |
| 6/30/2025 | 2,608 | 251 | 1,617 | 1,639 | N/A |
| 3/31/2025 | 2,530 | 234 | N/A | N/A | N/A |
| 12/31/2024 | 2,357 | 205 | 1,144 | 1,164 | N/A |
| 9/30/2024 | 2,142 | 189 | N/A | N/A | N/A |
| 6/30/2024 | 1,883 | 134 | N/A | N/A | N/A |
| 3/31/2024 | 1,849 | 140 | N/A | N/A | N/A |
| 12/31/2023 | 1,882 | 128 | 723 | 735 | N/A |
| 9/30/2023 | 1,092 | 140 | N/A | N/A | N/A |
| 6/30/2023 | 1,818 | 139 | N/A | N/A | N/A |
| 3/31/2023 | 1,570 | 115 | N/A | N/A | N/A |
| 1/1/2023 | 1,010 | 92 | 216 | 226 | N/A |
| 1/1/2022 | 825 | 57 | 464 | 471 | N/A |
| 12/31/2020 | 758 | 44 | -51 | -46 | N/A |
| 12/31/2019 | 549 | 36 | N/A | -23 | N/A |
| 12/31/2018 | 384 | 10 | N/A | 130 | N/A |
| 12/31/2017 | 318 | 18 | N/A | -96 | N/A |
| 12/31/2016 | 328 | 20 | N/A | 30 | N/A |
| 12/31/2015 | 346 | 18 | N/A | 8 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MRXDas prognostizierte Gewinnwachstum (14.9% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: MRXDie Erträge des Unternehmens (14.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.4% pro Jahr).
Hohe Wachstumserträge: MRXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: MRXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-7.3% pro Jahr).
Hohe Wachstumseinnahmen: MRXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-7.3% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: MRXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.2%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/07 22:36 |
| Aktienkurs zum Tagesende | 2026/05/07 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Marex Group plc wird von 13 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Benjamin Budish | Barclays |
| Christopher Allen | Citigroup Inc |
| Alexander Blostein | Goldman Sachs |